6 Biotechnology Stocks to Buy Now

Advertisement

Six Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Alnylam Pharmaceuticals (NASDAQ:ALNY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Alnylam Pharmaceuticals engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). In Portfolio Grader’s specific subcategory of Earnings Momentum, ALNY also gets an A. Shares of ALNY are up 2.6% from a month ago. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

DUSA Pharmaceuticals (NASDAQ:DUSA) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. DUSA Pharmaceuticals is a vertically integrated dermatology company that is developing and marketing pharmaceuticals for the treatment of skin conditions such as actinic keratoses and acne. The price of DUSA has gone up 1.5% from last month. For more information, get Portfolio Grader’s complete analysis of DUSA stock.

This week, Grifols (NASDAQ:GRFS) pushes up from a B to an A rating. Grifols S. A. develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

This is a strong week for Maxygen (NASDAQ:MAXY). The company’s rating climbs to B from the previous week’s C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. The stock currently has a trailing PE Ratio of 8.1. Since last month, shares of MAXY have risen 2.9%. For more information, get Portfolio Grader’s complete analysis of MAXY stock.

Dynavax Technologies (NASDAQ:DVAX) improves from a C to a B rating this week. Dynavax Technologies discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. Shares of the company are up 7.7% since last month. For more information, get Portfolio Grader’s complete analysis of DVAX stock.

This week, Allos Therapeutics‘s (NASDAQ:ALTH) ratings are up from a C last week to a B. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. ALTH shares have gone up 2.8% from the previous month. For more information, get Portfolio Grader’s complete analysis of ALTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2012/09/6-biotechnology-stocks-to-buy-now-alny-dusa-grfs/.

©2024 InvestorPlace Media, LLC